<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font24 { font-size : 24; } .font28 { font-size : 28; } .font29 { font-size : 29; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">virus </span>
   <span class="font29">influenza </span>
   <span class="font29">PMID: </span>
   <span class="font28">respiratory </span>
   <span class="font24">RSV </span>
   <span class="font20">treatment </span>
   <span class="font19">clinical </span>
   <span class="font18">syncytial </span>
   <span class="font17">NCT </span>
   <span class="font16">antiviral </span>
   <span class="font16">viruses </span>
   <span class="font16">infection </span>
   <span class="font16">viral </span>
   <span class="font16">study </span>
   <span class="font16">phase </span>
   <span class="font16">studies </span>
   <span class="font15">Middle </span>
   <span class="font15">East </span>
   <span class="font15">patients </span>
   <span class="font15">fusion </span>
   <span class="font15">syndrome </span>
   <span class="font15">efficacy </span>
   <span class="font15">human </span>
   <span class="font15">inhibitor </span>
   <span class="font15">protein </span>
   <span class="font14">Infect. </span>
   <span class="font14">trial </span>
   <span class="font14">infected </span>
   <span class="font14">Dis. </span>
   <span class="font14">activity </span>
   <span class="font14">healthy </span>
   <span class="font14">safety </span>
   <span class="font13">Influenza </span>
   <span class="font13">MERS-CoV </span>
   <span class="font13">Chemother. </span>
   <span class="font13">combination </span>
   <span class="font13">disease </span>
   <span class="font13">Antimicrob. </span>
   <span class="font13">demonstrated </span>
   <span class="font13">mice </span>
   <span class="font13">drug </span>
   <span class="font13">results </span>
   <span class="font13">approved </span>
   <span class="font13">currently </span>
   <span class="font13">novel </span>
   <span class="font13">{border-style </span>
   <span class="font13">Respiratory </span>
   <span class="font13">antibody </span>
   <span class="font13">coronavirus </span>
   <span class="font13">use </span>
   <span class="font12">Med. </span>
   <span class="font12">RNA </span>
   <span class="font12">infections </span>
   <span class="font12">px;} </span>
   <span class="font12">vitro </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">Agents </span>
   <span class="font12">Antiviral </span>
   <span class="font12">effective </span>
   <span class="font12">including </span>
   <span class="font12">infants </span>
   <span class="font12">lung </span>
   <span class="font12">monoclonal </span>
   <span class="font12">oseltamivir </span>
   <span class="font12">ribavirin </span>
   <span class="font12">adults </span>
   <span class="font12">severe </span>
   <span class="font12">shown </span>
   <span class="font12">therapy </span>
   <span class="font12">./AAC.- </span>
   <span class="font12">observed </span>
   <span class="font12">reduction </span>
   <span class="font12">showed </span>
   <span class="font12">(NCT) </span>
   <span class="font12">Inhibits </span>
   <span class="font12">group </span>
   <span class="font12">inhibitors </span>
   <span class="font12">mAb </span>
   <span class="font12">potential </span>
   <span class="font12">acute </span>
   <span class="font12">antibodies </span>
   <span class="font12">antivirals </span>
   <span class="font12">cell </span>
   <span class="font12">different </span>
   <span class="font12">new </span>
   <span class="font12">polymerase </span>
   <span class="font12">therapeutic </span>
   <span class="font11">development </span>
   <span class="font11">entry </span>
   <span class="font11">evaluate </span>
   <span class="font11">model </span>
   <span class="font11">recent </span>
   <span class="font11">therapies </span>
   <span class="font11">trials </span>
   <span class="font11">Health </span>
   <span class="font11">Preclinical </span>
   <span class="font11">Res. </span>
   <span class="font11">binding </span>
   <span class="font11">compared </span>
   <span class="font11">compound </span>
   <span class="font11">cotton </span>
   <span class="font11">prevention </span>
   <span class="font11">reduced </span>
   <span class="font11">replication </span>
   <span class="font11">target </span>
   <span class="font11">uncomplicated </span>
   <span class="font11">./j.antiviral... </span>
   <span class="font11">Al-Tawfiq </span>
   <span class="font11">Chem. </span>
   <span class="font11">Kim </span>
   <span class="font11">MEDI </span>
   <span class="font11">avian </span>
   <span class="font11">baloxavir </span>
   <span class="font11">challenge </span>
   <span class="font11">children </span>
   <span class="font11">collab: </span>
   <span class="font11">drugs </span>
   <span class="font11">health </span>
   <span class="font11">high </span>
   <span class="font11">infection, </span>
   <span class="font11">neuraminidase </span>
   <span class="font11">neutralizing </span>
   <span class="font11">oral </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">plasma </span>
   <span class="font11">titers </span>
   <span class="font11">treated </span>
   <span class="font11">used </span>
   <span class="font11">./s--- </span>
   <span class="font11">Centers </span>
   <span class="font11">Control </span>
   <span class="font11">Disease </span>
   <span class="font11">Drug </span>
   <span class="font11">United </span>
   <span class="font11">Viral </span>
   <span class="font11">Zumla </span>
   <span class="font11">adult </span>
   <span class="font11">animal </span>
   <span class="font11">broad-spectrum </span>
   <span class="font11">cases </span>
   <span class="font11">concluded </span>
   <span class="font11">determine </span>
   <span class="font11">double-blind, </span>
   <span class="font11">effect </span>
   <span class="font11">favipiravir </span>
   <span class="font11">highly </span>
   <span class="font11">load </span>
   <span class="font11">mAbs </span>
   <span class="font11">polyclonal </span>
   <span class="font11">preclinical </span>
   <span class="font11">region </span>
   <span class="font11">review </span>
   <span class="font11">significant </span>
   <span class="font11">small </span>
   <span class="font11">therapeutics </span>
   <span class="font11">tract </span>
   <span class="font11">(Accessed </span>
   <span class="font11">ALX- </span>
   <span class="font11">Available </span>
   <span class="font11">Clin. </span>
   <span class="font11">REGN </span>
   <span class="font11">Virus </span>
   <span class="font11">active </span>
   <span class="font11">administered </span>
   <span class="font11">aimed </span>
   <span class="font11">anti-RSV </span>
   <span class="font11">at: </span>
   <span class="font11">broad </span>
   <span class="font11">cells </span>
   <span class="font11">conducted </span>
   <span class="font11">conserved </span>
   <span class="font11">pandemic </span>
   <span class="font11">pharmacokinetics </span>
   <span class="font11">px; </span>
   <span class="font11">rats </span>
   <span class="font11">reported </span>
   <span class="font11">synthesis </span>
   <span class="font11">targeting </span>
   <span class="font11">using </span>
   <span class="font11">vivo </span>
   <span class="font11">volunteers </span>
   <span class="font11">{font-family </span>
   <span class="font11">(NCT). </span>
   <span class="font11">(RSV) </span>
   <span class="font11">Biol. </span>
   <span class="font11">FDA </span>
   <span class="font11">Furuta </span>
   <span class="font11">New </span>
   <span class="font11">Smee </span>
   <span class="font11">World </span>
   <span class="font11">addition, </span>
   <span class="font11">administration </span>
   <span class="font11">anti-influenza </span>
   <span class="font11">burden </span>
   <span class="font11">caused </span>
   <span class="font11">days </span>
   <span class="font11">developed </span>
   <span class="font11">developing </span>
   <span class="font11">font-size </span>
   <span class="font11">hospitalized </span>
   <span class="font11">immunoglobulin </span>
   <span class="font11">indicated </span>
   <span class="font11">infections. </span>
   <span class="font11">intravenous </span>
   <span class="font11">lethal </span>
   <span class="font11">options </span>
   <span class="font11">palivizumab </span>
   <span class="font11">preventing </span>
   <span class="font11">primary </span>
   <span class="font11">randomized, </span>
   <span class="font11">received </span>
   <span class="font11">seasonal </span>
   <span class="font11">significantly </span>
   <span class="font11">strains </span>
   <span class="font11">tolerated </span>
   <span class="font11">treat </span>
   <span class="font11">virus: </span>
   <span class="font10">ALN-RSV </span>
   <span class="font10">ALS- </span>
   <span class="font10">Byrn </span>
   <span class="font10">Clinical </span>
   <span class="font10">DAS, </span>
   <span class="font10">Detalle </span>
   <span class="font10">Favipiravir </span>
   <span class="font10">Front. </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Human </span>
   <span class="font10">JNJ- </span>
   <span class="font10">Jones </span>
   <span class="font10">Lee </span>
   <span class="font10">MERS-CoV-infected </span>
   <span class="font10">McBride </span>
   <span class="font10">Memish </span>
   <span class="font10">Microbiol. </span>
   <span class="font10">Nakamura </span>
   <span class="font10">Prevention </span>
   <span class="font10">RSV. </span>
   <span class="font10">Rev. </span>
   <span class="font10">Rossignol </span>
   <span class="font10">States </span>
   <span class="font10">Takashita </span>
   <span class="font10">Treatment </span>
   <span class="font10">Van </span>
   <span class="font10">action </span>
   <span class="font10">binds </span>
   <span class="font10">blocking </span>
   <span class="font10">case </span>
   <span class="font10">did </span>
   <span class="font10">double; </span>
   <span class="font10">early </span>
   <span class="font10">emerging </span>
   <span class="font10">hemagglutinin </span>
   <span class="font10">membrane </span>
   <span class="font10">outcomes </span>
   <span class="font10">placebo </span>
   <span class="font10">profile </span>
   <span class="font10">public </span>
   <span class="font10">published </span>
   <span class="font10">receptor </span>
   <span class="font10">resistance </span>
   <span class="font10">resistant </span>
   <span class="font10">safety, </span>
   <span class="font10">sialidase </span>
   <span class="font10">stalk </span>
   <span class="font10">subtypes </span>
   <span class="font10">symptoms </span>
   <span class="font10">targets </span>
   <span class="font10">tolerability, </span>
   <span class="font10">virus, </span>
   <span class="font10">viruses. </span>
   <span class="font10">./S-()- </span>
   <span class="font10">April </span>
   <span class="font10">Arabi </span>
   <span class="font10">Candidates </span>
   <span class="font10">Deng </span>
   <span class="font10">Expert </span>
   <span class="font10">GS- </span>
   <span class="font10">IgG </span>
   <span class="font10">Kumar </span>
   <span class="font10">Lancet </span>
   <span class="font10">Lim </span>
   <span class="font10">MHAAA </span>
   <span class="font10">Nat. </span>
   <span class="font10">Nitazoxanide </span>
   <span class="font10">Prevention, </span>
   <span class="font10">Proc. </span>
   <span class="font10">RSV, </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">Saudi </span>
   <span class="font10">Sci. </span>
   <span class="font10">Ther. </span>
   <span class="font10">Triana-Baltzer </span>
   <span class="font10">achieved </span>
   <span class="font10">antibody, </span>
   <span class="font10">associated </span>
   <span class="font10">available </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cap-dependent </span>
   <span class="font10">cause </span>
   <span class="font10">convalescent </span>
   <span class="font10">current </span>
   <span class="font10">diseases </span>
   <span class="font10">dose </span>
   <span class="font10">emergence </span>
   <span class="font10">endonuclease </span>
   <span class="font10">following </span>
   <span class="font10">fully </span>
   <span class="font10">half-life </span>
   <span class="font10">immune </span>
   <span class="font10">inhibit </span>
   <span class="font10">inhibitor, </span>
   <span class="font10">inhibits </span>
   <span class="font10">international </span>
   <span class="font10">known </span>
   <span class="font10">lower </span>
   <span class="font10">models </span>
   <span class="font10">neutralization </span>
   <span class="font10">nitazoxanide </span>
   <span class="font10">orally </span>
   <span class="font10">potent </span>
   <span class="font10">process </span>
   <span class="font10">protection </span>
   <span class="font10">recently </span>
   <span class="font10">recombinant </span>
   <span class="font10">risk </span>
   <span class="font10">solid; </span>
   <span class="font10">supportive </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(HN) </span>
   <span class="font10">./j.ijid... </span>
   <span class="font10">./journal.pone. </span>
   <span class="font10">Acad. </span>
   <span class="font10">Antivir. </span>
   <span class="font10">Antivirals </span>
   <span class="font10">Arabia </span>
   <span class="font10">Aschenbrenner </span>
   <span class="font10">Bonfanti </span>
   <span class="font10">Chan </span>
   <span class="font10">Deval </span>
   <span class="font10">Devincenzo </span>
   <span class="font10">Discovery </span>
   <span class="font10">Diseases </span>
   <span class="font10">Friesen </span>
   <span class="font10">Griffin </span>
   <span class="font10">Inhibitors </span>
   <span class="font10">Int. </span>
   <span class="font10">International </span>
   <span class="font10">JNJ-, </span>
   <span class="font10">Johnson </span>
   <span class="font10">Kallewaard </span>
   <span class="font10">Koszalka </span>
   <span class="font10">MERS </span>
   <span class="font10">Mishin </span>
   <span class="font10">Momattin </span>
   <span class="font10">Mustafa </span>
   <span class="font10">NAI </span>
   <span class="font10">Organization, </span>
   <span class="font10">Park </span>
   <span class="font10">Pediatr. </span>
   <span class="font10">Phase </span>
   <span class="font10">RI- </span>
   <span class="font10">Rabaan </span>
   <span class="font10">Respir. </span>
   <span class="font10">Results </span>
   <span class="font10">Roymans </span>
   <span class="font10">Shalhoub </span>
   <span class="font10">Society </span>
   <span class="font10">TMC </span>
   <span class="font10">Therapeutic </span>
   <span class="font10">University </span>
   <span class="font10">Viruses </span>
   <span class="font10">Wang </span>
   <span class="font10">Wong </span>
   <span class="font10">Wyde </span>
   <span class="font10">Xing </span>
   <span class="font10">Zhao </span>
   <span class="font10">acid </span>
   <span class="font10">analysis </span>
   <span class="font10">animals </span>
   <span class="font10">antigenic </span>
   <span class="font10">approach </span>
   <span class="font10">article </span>
   <span class="font10">beneficial </span>
   <span class="font10">bold </span>
   <span class="font10">broadly </span>
   <span class="font10">candidate </span>
   <span class="font10">care </span>
   <span class="font10">circulating </span>
   <span class="font10">class </span>
   <span class="font10">comparison </span>
   <span class="font10">compounds </span>
   <span class="font10">coronavirus: </span>
   <span class="font10">cost </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">day </span>
   <span class="font10">delivery </span>
   <span class="font10">development. </span>
   <span class="font10">effects </span>
   <span class="font10">em; </span>
   <span class="font10">epithelium </span>
   <span class="font10">epitope </span>
   <span class="font10">experimentally </span>
   <span class="font10">global </span>
   <span class="font10">high-risk </span>
   <span class="font10">however, </span>
   <span class="font10">illness </span>
   <span class="font10">immunogenicity </span>
   <span class="font10">improved </span>
   <span class="font10">infectious </span>
   <span class="font10">initiation </span>
   <span class="font10">isolated </span>
   <span class="font10">large </span>
   <span class="font10">leading </span>
   <span class="font10">levels </span>
   <span class="font10">long </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">low </span>
   <span class="font10">mechanism </span>
   <span class="font10">molecule </span>
   <span class="font10">mortality </span>
   <span class="font10">motavizumab </span>
   <span class="font10">mouse </span>
   <span class="font10">need </span>
   <span class="font10">needed </span>
   <span class="font10">novel, </span>
   <span class="font10">nucleoside </span>
   <span class="font10">obtained </span>
   <span class="font10">outbreak </span>
   <span class="font10">outbreaks </span>
   <span class="font10">participants </span>
   <span class="font10">patient </span>
   <span class="font10">people </span>
   <span class="font10">pharmacokinetic </span>
   <span class="font10">pimodivir </span>
   <span class="font10">population </span>
   <span class="font10">preterm </span>
   <span class="font10">produced </span>
   <span class="font10">promising </span>
   <span class="font10">prophylactic </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">proton </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized </span>
   <span class="font10">range </span>
   <span class="font10">recipients </span>
   <span class="font10">reduces </span>
   <span class="font10">reducing </span>
   <span class="font10">research </span>
   <span class="font10">retrospective </span>
   <span class="font10">serum </span>
   <span class="font10">started </span>
   <span class="font10">stem </span>
   <span class="font10">study, </span>
   <span class="font10">survival </span>
   <span class="font10">susceptibility </span>
   <span class="font10">symposium </span>
   <span class="font10">transplant </span>
   <span class="font10">treatment. </span>
   <span class="font10">vaccines </span>
   <span class="font10">variants </span>
   <span class="font10">virus. </span>
   <span class="font10">viruses, </span>
  </p>
 </body>
</html>
